HCMV-reactive T cells and uses therefor
AssigneeCity of Hope
InventorDon J. Diamond
Life of this patent
Estimating the term…
Abstract
The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are capable of activating CTLs and CTLps in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Peptide and lipopeptide vaccines, with and without adjuvants, also are disclosed. Cellular vaccines comprising the peptides form a further embodiment of this invention.
Claims6
Enriched activated HCMV-reactive T cells that recognize a peptide of SEQ ID NO:1.
Dependencies are inferred from the claim text.